STOCK TITAN

GRI Bio, Inc. - GRI STOCK NEWS

Welcome to our dedicated page for GRI Bio news (Ticker: GRI), a resource for investors and traders seeking the latest updates and insights on GRI Bio stock.

GRI Bio, Inc. (symbol: GRI) is a pioneering clinical-stage biotech company dedicated to fundamentally transforming the treatment of inflammatory diseases. Specializing in the innovative development of therapies targeting dysregulated immune responses, GRI Bio focuses on inflammatory, fibrotic, and autoimmune disorders.

The company's core technology revolves around Natural Killer T (NKT) cell-based therapies. NKT cells are unique as they possess characteristics of both NK and T cells, serving as a critical bridge between innate and adaptive immune responses. Notably, Type 1 NKT cells are instrumental in initiating and propagating inflammatory responses and mediate the hepatic injury observed in liver diseases.

GRI Bio's lead program, GRI-0621, is an orally administered small molecule that acts as an inhibitor of Type 1 NKT cells. This groundbreaking therapy is being developed for the treatment of acute liver failure, aiming to curb hepatic inflammation by restoring immune system balance. Additionally, GRI-0621 serves as a RAR-beta and gamma dual agonist, further enhancing its therapeutic potential.

In addition to GRI-0621, the company boasts other promising candidates including GRI-0803, a novel oral agonist targeting Type 2 NKT cells. This candidate holds significant promise as a potential treatment for autoimmune disorders, further broadening GRI Bio's therapeutic arsenal.

GRI Bio's dedication to innovation and commitment to addressing unmet medical needs position it as a significant player in the biotech industry. With ongoing advancements and a robust pipeline, GRI Bio continues to drive forward in its mission to improve patient outcomes through cutting-edge science and targeted therapies.

Rhea-AI Summary

GRI Bio (NASDAQ: GRI), a biotechnology firm specializing in NKT cell modulators for inflammatory, fibrotic, and autoimmune diseases, has released a Virtual Investor 'What This Means' segment. CEO Marc Hertz, PhD, emphasizes the significance of interim data from their Phase 2a biomarker study on Idiopathic Pulmonary Fibrosis (IPF) for the GRI-0621 program. This segment delves into the implications of the data for GRI Bio's ongoing IPF study. The video is available for viewing on the Virtual Investor website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.85%
Tags
none
-
News
Rhea-AI Summary

GRI Bio, a biotechnology company, has regained compliance with Nasdaq listing standards as of July 2, 2024. The company, known for its Natural Killer T cell modulators targeting inflammatory, fibrotic, and autoimmune diseases, received a notice from Nasdaq indicating that it meets all requirements for continued listing on the Nasdaq Capital Market. Consequently, the scheduled hearing before the Hearings Panel has been canceled. CEO Marc Hertz expressed excitement over this development and emphasized the company's focus on advancing their core business objectives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.46%
Tags
none
-
Rhea-AI Summary

GRI Bio has published promising preclinical data for its lead program, GRI-0621, in the American Journal of Respiratory and Critical Care Medicine. The study shows that inhibiting type 1 invariant NKT (iNKT) cell activity can reduce fibrosis and inflammation in a mouse model of Idiopathic Pulmonary Fibrosis (IPF). Compared to controls, GRI-0621-treated mice exhibited significant improvements in lung histology, decreased fibrosis scores, and reduced lung inflammation. The company is advancing a Phase 2a biomarker study of GRI-0621 in IPF patients, with interim results expected in Q3 2024 and topline data in Q4 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.68%
Tags
Rhea-AI Summary

GRI Bio, a biotechnology company specializing in Natural Killer T (NKT) cell modulators for treating inflammatory, fibrotic, and autoimmune diseases, is set to present at the 8th Annual IPF Summit. The event will take place from August 20-22, 2024, in Boston, MA.

Vipin Kumar Chaturvedi, PhD, the Chief Scientific Officer of GRI Bio, will deliver a presentation titled 'Examining the Underlying Mechanism & Patients Subject to the Therapeutic Potential of NKT-Cell Targeting.' This session will be part of the 'Exploring the Clinical Promise of Emerging Modalities & Targets from NKT-Cells to ADCs, Small RNA Inhibitors, Nanotechnology for Fibrosis Control' segment scheduled for August 22, 2024, from 8:00-8:30 AM ET.

For more details, attendees are encouraged to visit the conference website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
conferences
-
Rhea-AI Summary

GRI Bio announced the closing of its $4.0 million public offering. The offering included 2,185,793 shares of common stock and Series C-1 and C-2 warrants to purchase additional shares, all priced at $1.83 per share. The Series C-1 warrants expire five years from the initial exercise date, while the Series C-2 warrants expire eighteen months from the initial exercise date. H.C. Wainwright & Co. acted as the exclusive placement agent. Gross proceeds before fees and expenses were approximately $4.0 million, with potential additional gross proceeds of $8.0 million if all warrants are exercised for cash. Proceeds will be used for product development, working capital, and general corporate purposes. The offering was made via an effective registration statement on Form S-1, declared effective by the SEC on June 26, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
-
Rhea-AI Summary

GRI Bio has been granted Patent No. 10-2665487 by the Korean Intellectual Property Office for its Natural Killer T (NKT) cell modulators.

The patent covers compositions and methods for modulating type 2 and/or type 1 invariant NKT (iNKT) cells to treat inflammatory, fibrotic, and autoimmune conditions through the administration of a Retinoic Acid Receptor (RAR) agonist.

CEO Marc Hertz emphasized the importance of this patent in expanding their intellectual property portfolio and advancing their clinical programs.

GRI Bio's lead program, GRI-0621, is currently in a Phase 2a trial for Idiopathic Pulmonary Fibrosis (IPF), with interim data expected in Q3 2024 and topline results in Q4 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.1%
Tags
none
Rhea-AI Summary

GRI Bio, a biotechnology company specializing in Natural Killer T cell modulators for treating inflammatory, fibrotic, and autoimmune diseases, has announced the pricing of a $4 million public offering. This offering includes 2,185,793 shares of common stock or equivalents, Series C-1 and Series C-2 warrants to purchase up to 2,185,793 shares each, all priced at $1.83 per share or equivalent. The Series C-1 warrants will expire five years after the initial exercise date, and the Series C-2 warrants will expire eighteen months after. The offering is expected to close around June 28, 2024. H.C. Wainwright & Co. is acting as the exclusive placement agent. The gross proceeds from the offering could increase by an additional $8 million if all Series Warrants are fully exercised. The net proceeds will be used for product candidate development, working capital, and general corporate purposes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.1%
Tags
-
News
Rhea-AI Summary

On June 14, 2024, GRI Bio announced a 1-for-13 reverse stock split, approved by stockholders on June 7, 2024. It will take effect on June 17, 2024, at 4:01 p.m. ET, and GRI's common stock will begin trading on a split-adjusted basis on June 18, 2024, under the ticker 'GRI' with a new CUSIP number 3622AW 304. The split aims to increase the share price to meet Nasdaq's minimum bid price requirement. Post-split, 13 shares will convert into one, reducing outstanding shares from 6,605,271 to around 508,091, while the authorized shares remain unchanged. Fractional shares will be paid in cash. Adjustments will also be made to stock options, warrants, and convertible securities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.97%
Tags
-
Rhea-AI Summary

GRI Bio (NASDAQ: GRI) will present at the Virtual Investor Pitch Conference on June 18, 2024, at 11:00 AM ET. The company specializes in developing Natural Killer T (NKT) cell modulators for treating inflammatory, fibrotic, and autoimmune diseases. During the event, CEO Marc Hertz, PhD, will deliver an elevator pitch and discuss upcoming milestones. Attendees can submit questions live, with responses given within the allotted time. The live video webcast and a replay available for 90 days can be accessed on GRI Bio's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.21%
Tags
conferences
Rhea-AI Summary

GRI Bio (NASDAQ: GRI) has participated in a Virtual Investor 'What This Means' segment, showcasing positive preclinical data from its Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) programs. The data was presented at the 2024 American Thoracic Society International Conference and the 14th International Congress on Autoimmunity.

Key personnel, including CEO Marc Hertz, discussed the implications of these findings for the company's IPF program (GRI-0621) and SLE development programs (GRI-0803 and GRI-0124). The company reiterated 2024 as a pivotal year, with significant milestones expected, such as interim and topline results from Phase 2a biomarker studies for GRI-0621, and completion of IND-enabling studies and initial clinical trials for GRI-0803.

The Virtual Investor segment is now available online for further insights.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.53%
Tags

FAQ

What does GRI Bio, Inc. specialize in?

GRI Bio, Inc. specializes in developing therapies targeting serious diseases associated with dysregulated immune responses, including inflammatory, fibrotic, and autoimmune disorders.

What is GRI Bio's lead program?

GRI Bio's lead program is GRI-0621, an oral therapeutic that inhibits Type 1 NKT cells and is being developed for the treatment of acute liver failure.

How does GRI-0621 work?

GRI-0621 works by inhibiting the activity of Type 1 NKT cells, helping to restore balance in the immune system and reduce hepatic inflammation.

What other products is GRI Bio developing?

GRI Bio is also developing GRI-0803, an oral agonist targeting Type 2 NKT cells, which shows promise as a potential treatment for autoimmune disorders.

What makes NKT cells unique?

NKT cells share properties of both NK and T cells and serve as a functional link between the innate and adaptive immune responses, playing a critical role in initiating and propagating inflammatory responses.

What stage is GRI Bio in?

GRI Bio is a clinical-stage biotech company, actively developing and testing its therapeutic candidates.

Who can I contact for investor-related inquiries?

For investor-related inquiries, you can contact the JTC Team, LLC with Jenene Thomas at (833) 475-8247 or via email at GRI@jtcir.com.

What is the significance of GRI-0803?

GRI-0803 is significant as it targets Type 2 NKT cells, offering potential new treatments for autoimmune disorders, which are currently underserved by existing therapies.

Does GRI Bio have any partnerships?

While the specific partnerships are not detailed in the description, GRI Bio's ongoing development projects suggest potential collaborations with research institutions and pharmaceutical companies.

How can I stay updated on GRI Bio's latest news?

You can stay updated on GRI Bio's latest news by visiting their website, following their press releases, or contacting their investor relations at the provided contact details.

GRI Bio, Inc.

Nasdaq:GRI

GRI Rankings

GRI Stock Data

1.05M
600.00k
1.7%
2.99%
0.25%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
LA JOLLA